Related Experiment Video

Updated: Mar 25, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K

EGFR-targeted mAb therapy modulates autophagy in head and neck squamous cell carcinoma through NLRX1-TUFM protein

Y Lei1, B A Kansy1, J Li1

  • 1Department of Otolaryngology, University of Pittsburgh Cancer Institute, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Oncogene
|February 16, 2016
PubMed

Insights

Tumor resistance to EGFR-targeted therapy in head and neck cancer involves autophagy. Inhibiting autophagy and targeting the NLRX1-TUFM complex may improve treatment efficacy, with p62 as a potential resistance biomarker.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cellular Biology

Background:

  • Epidermal growth factor receptor (EGFR)-targeted therapy is crucial for head and neck squamous cell carcinoma (HNSCC).
  • Tumor resistance to EGFR inhibitors is a significant clinical challenge.
  • Autophagy is an emerging mechanism contributing to treatment resistance in HNSCC.

Purpose of the Study:

  • To investigate the role of autophagy in HNSCC resistance to EGFR-targeted therapy.
  • To identify molecular players and biomarkers associated with autophagy modulation and treatment response.
  • To explore novel therapeutic strategies combining EGFR blockade with autophagy inhibition.

Main Methods:

  • Utilized cetuximab to block EGFR in HNSCC cells and analyzed autophagic responses.
  • Investigated the function of the NLRX1-TUFM protein complex in promoting autophagic flux.
  • Examined the interaction of TUFM with Beclin-1 and its role in mitochondrial recruitment and polyubiquitination.
  • Assessed endoplasmic reticulum stress signaling in relation to autophagy.
  • Analyzed tumor specimens from a neoadjuvant clinical trial to correlate protein expression with treatment response.

Main Results:

  • EGFR blockade with cetuximab induced varied autophagic responses, influencing cancer cell susceptibility.
  • Inhibition of autophagy sensitized HNSCC cells to EGFR blockade.
  • Identified a novel NLRX1-TUFM protein complex essential for promoting autophagic flux.
  • TUFM was found to recruit Beclin-1 to mitochondria, promoting its polyubiquitination and interfering with Rubicon interaction.
  • Increased expression of SQSTM1/p62 was associated with poor response to cetuximab therapy.

Conclusions:

  • Autophagy plays a critical role in HNSCC resistance to EGFR-targeted therapy.
  • The NLRX1-TUFM complex represents a novel mechanism promoting autophagy in response to EGFR inhibition.
  • Targeting the NLRX1-TUFM complex and autophagy inhibition can enhance therapeutic efficacy.
  • SQSTM1/p62 may serve as a predictive biomarker for cetuximab response in HNSCC patients.

More Related Videos

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma12:03

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

20.1K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K